Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

Talaris Therapeutics logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Key Stats

Today's Range
$23.25
$24.55
50-Day Range
$12.36
$28.36
52-Week Range
$0.89
$27.95
Volume
154,328 shs
Average Volume
386,531 shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Stock News Headlines

Tourmaline Bio, Inc. (TRML)
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Longitude Venture Partners III, L.P.'s Net Worth
See More Headlines

TALS Stock Analysis - Frequently Asked Questions

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03.

Talaris Therapeutics (TALS) raised $150 million in an IPO on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talaris Therapeutics investors own include Graphite Bio (GRPH), Vaccitech (VACC), Achilles Therapeutics (ACHL), Allogene Therapeutics (ALLO), Cytec Industries (CYT), Immunocore (IMCR) and Century Therapeutics (IPSC).

Company Calendar

Last Earnings
11/12/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

Net Income
$-73,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.33 per share

Miscellaneous

Free Float
35,708,000
Market Cap
$1.03 billion
Optionable
Not Optionable
Beta
2.18
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:TALS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners